ProCE Banner Activity

SELECT Pooled Analysis: MACE and VTE Across Upadacitinib Studies in Patients With Rheumatoid Arthritis

Slideset Download
Conference Coverage
Analysis of pooled data from 5 phase III RCTs in RA patients suggests that upadacitinib causes no apparent increase in MACE or VTE over 24 months.

Released: November 14, 2019

Expiration: November 12, 2020

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Gilead

Mallinckrodt Pharmaceuticals